Table 2 Fasting glucose and insulin levels with corresponding treatment regimens
Day after hospitalization | FG mg/dL (mmol/L) | Insulin μU/mL | Treatment regimen (Analysis by CGM) [Analysis of C-peptide responses to each meal] |
|---|---|---|---|
1 | Asp 4–4-4, stopped insulin glargine | ||
2 | 62 (3.4) | 4500 | |
3 | 47 (2.6) | ||
5 | 55 (3.1) | ||
8 | Stopped Asp from dinner | ||
10 | 358 (19.9) | 2500 | |
16 | 362 (20.1) | Start Asp 4–6-4 | |
20 | 61 (3.4) | Stopped Asp, start RHI 4–4-4 | |
30 | RHI 4–4-4, add LIRA 0.3 mg QD | ||
38 | 77 (4.3) | RHI 4–4-4 + LIRA 0.6 mg QD | |
41 | RHI 3–3-3 + LIRA 0.9 mg QD | ||
43 | 65 (3.6) | 3570 | |
45 | 79 (4.4) | Stopped RHI, start Lis 3–3-3 + LIRA 0.9 mg QD | |
51 | 52 (2.9) | Lis 3–3-3 + LIRA 0.9 mg QD, add Voglibose 0.2 mg QD | |
53 | 51 (2.8) | 3500 | (CGM in Fig. 2a) |
54 | [C-peptide measurement in Fig. 3] | ||
56 | 63 (3.5) | Lis 2–3-3 + LIRA 0.9 mg QD + Voglibose 0.2 mg QD | |
58 | 68 (3.8) | Lis 2–3-3 + LIRA 0.9 mg QD + Voglibose 0.2 mg QD, add Mitiglinide 10 mg TID | |
59 | 46 (2.6) | LIRA 0.9 mg QD + Voglibose 0.2 mg QD + Mitiglinide 10 mg TID, stopped Lis [C-peptide measurement in Fig. 3] | |
61 | 91 (5.1) | ||
63 | 95 (5.3) | (CGM in Fig.2b) | |
66 | 167 (9.3) | 2640 | |
67 | 100 (5.6) |